Genc H, Dogru T, Kara M, Tapan S, Nuri EC, Acikel C, Karslioglu Y, Bagci S

Idioma: Ingles.
Referencias bibliográficas: 38
Paginas: 380-387
Archivo PDF: 113.24 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8: 4-8.

2. Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009; 8: 18-24.

3. Chávez-Tapia NN, Uribe M, Ponciano-Rodríguez G, Medina- Santillán R, Méndez-Sánchez N. New insights into the pathophysiology of nonalcoholic fatty liver disease. Ann Hepatol 2009; 8: 9-17

4. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957–69.

5. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008; 15: 91-101.

6. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 9: 299-314.

7. Bemdt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-6.

8. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): A link between NAD biology, metabolism, and diseases. Curr Pharm Des 2009; 15: 20-8.

9. Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor [PBEF]/visfatin: visfatin novel mediator of innate immunity. J Leukoc Biol 2008; 83: 804-16.

10. Kukla M, Ciupinska-Kajor M, Kajor M, Wylezol M, Zwirska- Korczala K, Hartleb M, Berdowska A, et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol 2010; 61: 147-53.

11. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damås JK, Haaland T, et al. Intracellular nicotinamide phosphoribosylotransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 3039-47.

12. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, Alvarez T et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009; 54: 1772-7.

13. Diagnosis and Classification of Diabetes Mellitus. ADA position statements. Diabetes Care 2011; 34: 62-9.

14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28; 412-9.

16. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.

17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.

18. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol [Oxf] 2008; 69: 878-84.

19. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-9.

20. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-21.

21. Gaddipati R, Sasikala M, Padaki N, Mukherjee RM, Sekaran A, Jayaraj-Mansard M, Rabella P, et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol 2010; 9: 266-70.

22. Gunes F, Akbal E, Cakir E, Akyurek O, Altunbas M, Ozbek M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012; 51: 553-7.

23. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, D’Angelo A, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res 2011; 34: 145-51.

24. Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril 2010; 93: 880-4.

25. Ibáñez L, López-Bermejo A, Díaz M, Enríquez G, Valls C, de Zegher F. Pioglitazone [7.5 mg/day] added to flutamide- metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clin Endocrinol [Oxf] 2008; 68: 317-20.

26. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, Jungbauer A, Wolzt M. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008; 38: 820-6.

27. Dogru T, Sonmez A, Tasci I, Yilmaz MI, Erdem G, Erturk H, Bingol N, et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 2007; 21: 173-5.

28. Erdem G, Dogru T, Tasci I, Bozoglu E, Muhsiroglu O, Tapan S, Ercin CN, et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 82: 214-8.

29. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-9.

30. Curat CA, Wegner V, Sengene’s C, Miranville A, Tonus C, Buse R, Bouloumié A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-7.

31. Dahl T, Ranheim T, Holm S, Berge R, Aukrust P, Halvorsen B. Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages. Eur J Clin Invest 2011; 41: 1098- 104.

32. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-37.

33. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-27.

34. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-58.

35. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3–L1 adipocytes. Am J Physiol Endocrinol Metab 2005; 289: 586-90.

36. Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Berdowska A, Rybus-Kalinowska B, et al. Visfatin serum levels in chronic hepatitis C patients. J Viral Hepat 2010; 17: 254-60.

37. de Boer JF, Bahr MJ, Boker KH, Manns MP, Tietge UJ. Plasma levels of PBEF/Nampt/ visfatin are decreased in patients with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: 196-201.

38. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine exerts direct cardioprotective effects. J Cell Mod Med 2008; 12: 1395-403.